PCR产物固相杂交酶联显色观察白细胞介素-2联合干扰素-α治疗慢性丙型肝炎疗效

Polymerase chain reaction and hybrid ELISA to observe the effect of combination therapy of IL-2 and IFN-α for chronic hepatitis C

目的 建立一步法基因扩增产物固相杂交酶联免疫吸附方法并用于临床观察白细胞介素 2 (IL 2 )联合干扰素 α(IFN α)治疗慢性丙型肝炎的疗效。方法 7例患者中有 4例患者接受IL 2和IFN α联合治疗 ,其中 2例为IFN α单独或联合抗病毒药物治疗后复发者 ,未接受过抗病毒药物治疗者 2例 ,疗程为一年。余下的 3例患者为单独使用IFN α治疗者。同时采用一步法基因扩增产物固相杂交酶联免疫吸附方法检测血清丙型肝炎病毒核酸 (HCVRNA)滴度评价疗效。结果 IL 2联合干扰素治疗对干扰素治疗后复发者仍有效 ,完全应答率为 10 0 % ;对未接受过抗病毒药物治疗者也有效 ,完全应答率为 5 0 %。结论 白细胞介素 2联合干扰素可作为初次治疗及复发后再治疗的选择方案。而一步法基因扩增产物固相杂交酶联显色检测血清HCV RNA滴度的方法可快速、特异、灵敏地反应出治疗过程中HCV RNA量的变化 ,为临床治疗提供可靠的疗效判定指标。

Objective To build a method of HCV-Reverse transcription polymerase chain reaction and hybrid ELISA to observe the effect of combination therapy of IL-2 and IFN-α in chronic hepatitis C. Methods Two patients who have initial response to combination or monotherapy of IFN and then relapse with another two patients who are not previously treated with antiviral therapy (naive) are treated with combination therapy of IL-2 and IFN.Three are treated with IFN alone (control). In order to evaluate and judge the effect of antiviral therapy more visually, we use a method of HCV-Reverse transcription polymerase chain reaction and hybrid ELISA to detect the titers of serum HCV-RNA. Results The substantial response rate of patients who have initial response to combination or monotherapy of IFN and then relapse is 100%;while that of the patients who are not previously treated with antiviral therapy (naive) is 50%.Conclusion Combination therapy of IL-2 and IFN appears to be effective in relapsers and naive patients.The method of HCV-Reverse transcription polymerase chain reaction and hybrid ELISA is sensitive, specific and rapid in reflecting the changes of serum HCV-RNA titer in duration of therapy.